NCT02118285 arm group 4c4ac06fd21d631f7c21330fa8027002 [clinicaltrials_resource:NCT02118285/arm-group/4c4ac06fd21d631f7c21330fa8027002]
NK cells [clinicaltrials_resource:7cc8fc8b2a923196f9504f28f7b62113]Fludarabine [clinicaltrials_resource:988aa6ab53acf347160d4078072a67d6]INCB024360 [clinicaltrials_resource:a30dc039c5e88db5bd628b7860a89742]IL-2 [clinicaltrials_resource:de7ade5ebd8652a3abf995dfa932e7d0]Cyclophosphamide [clinicaltrials_resource:ec6a84affd4c743613ff49a9b7b6cc21]clinicaltrials:NCT02118285
arm group [clinicaltrials_vocabulary:arm-group]
NCT02118285 arm group 4c4ac06fd21d631f7c21330fa8027002 [clinicaltrials_resource:NCT02118285/arm-group/4c4ac06fd21d631f7c21330fa8027002]
Bio2RDF identifier
NCT02118285/arm-group/4c4ac06fd21d631f7c21330fa8027002
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltri ...... 4ac06fd21d631f7c21330fa8027002
description [clinicaltrials_vocabulary:description]
Haploidentical donor NK cells ...... inues twice daily for 90 days.
identifier
clinicaltrials_resource:NCT02118285/arm-group/4c4ac06fd21d631f7c21330fa8027002
title
NCT02118285 arm group 4c4ac06fd21d631f7c21330fa8027002
@en
type
label
NCT02118285 arm group 4c4ac06f ...... ac06fd21d631f7c21330fa8027002]
@en